Anbio Biotechnology (NNNN) stock
Close on Nov 12, 2026Market cap $546.79MP/E 25.9Yield –
Anbio Biotechnology grew revenue 5.6% to $8.65M over fiscal 2025. Operating income rose 189.1% to $5.77M, moving the operating margin from 24.4% to 66.7%. At the latest close the market valued the company at $546.79M, 25.9 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- $546.79M
- P/E ratio
- 25.9
- Price to sales
- 63.24
- Price to book
- 18.13
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $8.65M
- Net income
- $6.40M
- EPS, diluted
- $0.15
Trading
- Previous close
- $4.05
- Open
- $3.90
- Day's range
- $3.80 – $3.96
- Volume
- 15,516
- Average volume (20 days)
- 52,069
- 52-week range
- $3.09 – $44.73
- RSI (14 days)
- 43.6
- Volatility (1 year)
- 114.4%
- Relative volume
- 0.13×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NNNN | S&P 500 | Difference | NNNN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.8% | -2.7% | −11.1 pts | ||
| 3 months | -61.6% | -1.7% | −59.8 pts | ||
| Year to date | -87.4% | +11.9% | −99.3 pts | ||
| 1 year | -83.1% | +12.0% | −95.0 pts |
Five years at a glance
Fiscal years 2021 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases Anbio Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Anbio Biotechnology
In Vitro & In Vivo Diagnostic Substances
Anbio Biotechnology is a biotechnology company that designs and supplies in vitro diagnostic (IVD) solutions, including instruments, assays, reagents, and retail self-test products. Its offerings span testing technologies such as fluorescent immunoassay (FIA), chemiluminescent immunoassay (ChLIA), molecular testing, dry chemistry, and lateral flow immunoassay (LFIA). These diagnostic solutions address respiratory conditions, COVID-19, and various non-respiratory health indications. The company sells to consumers, healthcare providers, health systems, enterprises, and governmental procurement bodies.
Company profile, executives and historyAnbio Biotechnology stock: common questions
What is Anbio Biotechnology's stock price?
NNNN closed at $3.80 on Nov 12, 2026, down 6.17% on the day. Over the past 52 weeks it traded between $3.09 and $44.73.
What is Anbio Biotechnology's market cap?
Anbio Biotechnology was worth $546.79M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is NNNN's P/E ratio?
NNNN trades at 25.9 times earnings, based on diluted earnings per share of $0.15 over fiscal 2025.
How much revenue does Anbio Biotechnology make?
Anbio Biotechnology reported revenue of $8.65M for fiscal 2025, up 5.6% from a year earlier.
Does Anbio Biotechnology pay a dividend?
No. Anbio Biotechnology has not paid a cash dividend over the last twelve months.
How has NNNN stock performed over the past year?
Including dividends, NNNN returned -83.1% over the past year, against +12.0% for the S&P 500.
How many NNNN shares are sold short?
0M shares were sold short at the latest FINRA report, 0.02% of the float, or 1.0 days of average trading volume.
Who are Anbio Biotechnology's competitors?
Companies most similar to Anbio Biotechnology by business, industry and size include BMRA, TRIB, IMDX, ICCC, TKNO.
See a number that looks wrong?